International audiencePre-existing immunity to adeno-associated virus (AAV) is highly prevalent in humans and can profoundly impact transduction efficiency. Despite the relevance to AAV-mediated gene transfer, relatively little is known about the fate of AAV vectors in the presence of neutralizing antibodies (NAbs). Similarly, the effect of binding antibodies (BAbs), with no detectable neutralizing activity, on AAV transduction is ill defined. Here, we delivered AAV8 vectors to mice carrying NAbs and demonstrated that AAV particles are taken up by both liver parenchymal and non-parenchymal cells; viral particles are then rapidly cleared, without resulting in transgene expression. In vitro, imaging of hepatocytes exposed to AAV vectors pre-i...
International audienceOver the past decade, vectors derived from adeno-associated virus (AAV) have e...
International audienceOver the past decade, vectors derived from adeno-associated virus (AAV) have e...
International audienceOver the past decade, vectors derived from adeno-associated virus (AAV) have e...
International audiencePre-existing immunity to adeno-associated virus (AAV) is highly prevalent in h...
International audiencePre-existing immunity to adeno-associated virus (AAV) is highly prevalent in h...
International audiencePre-existing immunity to adeno-associated virus (AAV) is highly prevalent in h...
International audiencePre-existing immunity to adeno-associated virus (AAV) is highly prevalent in h...
International audiencePre-existing immunity to adeno-associated virus (AAV) is highly prevalent in h...
International audiencePre-existing immunity to adeno-associated virus (AAV) is highly prevalent in h...
Pre-existing immunity to adeno-associated virus (AAV) is highly prevalent in humans and can profound...
International audienceGene therapy with adeno-associated virus (AAV) vectors has demonstrated safety...
Gene therapy utilizing adeno-associated viral (AAV) vectors has experienced much success in the clin...
Gene therapy utilizing adeno-associated viral (AAV) vectors has experienced much success in the clin...
International audienceOver the past decade, vectors derived from adeno-associated virus (AAV) have e...
International audienceOver the past decade, vectors derived from adeno-associated virus (AAV) have e...
International audienceOver the past decade, vectors derived from adeno-associated virus (AAV) have e...
International audienceOver the past decade, vectors derived from adeno-associated virus (AAV) have e...
International audienceOver the past decade, vectors derived from adeno-associated virus (AAV) have e...
International audiencePre-existing immunity to adeno-associated virus (AAV) is highly prevalent in h...
International audiencePre-existing immunity to adeno-associated virus (AAV) is highly prevalent in h...
International audiencePre-existing immunity to adeno-associated virus (AAV) is highly prevalent in h...
International audiencePre-existing immunity to adeno-associated virus (AAV) is highly prevalent in h...
International audiencePre-existing immunity to adeno-associated virus (AAV) is highly prevalent in h...
International audiencePre-existing immunity to adeno-associated virus (AAV) is highly prevalent in h...
Pre-existing immunity to adeno-associated virus (AAV) is highly prevalent in humans and can profound...
International audienceGene therapy with adeno-associated virus (AAV) vectors has demonstrated safety...
Gene therapy utilizing adeno-associated viral (AAV) vectors has experienced much success in the clin...
Gene therapy utilizing adeno-associated viral (AAV) vectors has experienced much success in the clin...
International audienceOver the past decade, vectors derived from adeno-associated virus (AAV) have e...
International audienceOver the past decade, vectors derived from adeno-associated virus (AAV) have e...
International audienceOver the past decade, vectors derived from adeno-associated virus (AAV) have e...
International audienceOver the past decade, vectors derived from adeno-associated virus (AAV) have e...
International audienceOver the past decade, vectors derived from adeno-associated virus (AAV) have e...